DURECT Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRRX research report →
Companywww.durect.com
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
- CEO
- James E. Brown D.V.M.
- IPO
- 2000
- Employees
- 21
- HQ
- Cupertino, CA, US
Price Chart
Valuation
- Market Cap
- $59.31M
- P/E
- 73.47
- P/S
- 48.58
- P/B
- 15.06
- EV/EBITDA
- -4.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.97%
- Op Margin
- -1045.54%
- Net Margin
- 66.09%
- ROE
- 13.14%
- ROIC
- -188.15%
Growth & Income
- Revenue
- $2.03M · -76.24%
- Net Income
- $-8,324,000 · 69.87%
- EPS
- $-0.27 · 77.87%
- Op Income
- $-18,912,000
- FCF YoY
- 44.62%
Performance & Tape
- 52W High
- $2.64
- 52W Low
- $0.48
- 50D MA
- $1.41
- 200D MA
- $0.91
- Beta
- 0.93
- Avg Volume
- 1.19M
Get TickerSpark's AI analysis on DRRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 11, 25 | BROWN JAMES E | sell | 103,077 |
| Sep 11, 25 | Robertson Judith J. | sell | 5,500 |
| Sep 11, 25 | Robertson Judith J. | sell | 5,500 |
| Sep 11, 25 | Robertson Judith J. | sell | 5,500 |
| Sep 11, 25 | Robertson Judith J. | sell | 5,500 |
| Sep 11, 25 | Robertson Judith J. | other | 41,113 |
| Sep 11, 25 | Robertson Judith J. | sell | 7,000 |
| Sep 11, 25 | BROWN JAMES E | other | 8,000 |
| Sep 11, 25 | BROWN JAMES E | sell | 96,959 |
| Sep 11, 25 | BROWN JAMES E | sell | 36,720 |
Our DRRX Coverage
We haven't published any research on DRRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DRRX Report →